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a b s t r a c t
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening clinical syndrome characterized by dysregula-
tion of the immune system. Impaired function of cytotoxic T cells and natural killer cells is often seen, and T-
cell malignancies represent most cases of lymphoma-associated HLH. HLH associated with B-cell lymphoma is
rare. We describe a case of a 30-year-old manwho presented with fever, splenomegaly, and hyperferritinemia.
Bonemarrow biopsy revealed T-cell/histiocyte-rich large B-cell lymphoma, a rare, aggressive B-cell malignancy.
This case highlights the interplay between a pro-inﬂammatory cytokine microenvironment and tumor-
mediated immune suppression, and addresses the importance of accurately diagnosing these entities for
appropriate clinical management.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Hemophagocytic lymphohistiocytosis (HLH) is an uncom-
mon, hyperinﬂammatory syndrome that is often fatal when
treatment is delayed [1]. Diagnosis may be difﬁcult due to the
wide range of symptoms associated with HLH and lack of
speciﬁc diagnostic tests. Genetic causes of familial HLH relate
to defects in cytotoxic granule exocytosis or function, whereas
the acquired or secondary form is often associated with
infection, malignancy, or autoimmune/immunodeﬁciency
conditions. Defects in cytotoxic T cells and natural killer
(NK) cells are seen in nearly all cases of HLH [1]. Hematologic
neoplasms account for the majority of malignancy-associated
HLH, and T-cell malignancies predominate. HLH associated
with underlying B-cell lymphoma is rare, and seems to occur
in older patients with a low incidence of marrow involvement
by lymphoma [2]. Here, we describe a case of HLH arising in a
young patient with diffuse marrow involvement by T-cell/
histiocyte-rich large B-cell lymphoma (THRLBCL), a subtype
representing 1–3% of diffuse large B-cell lymphomas (DLBCL)
with a characteristic background of cytotoxic T cells and
histiocytes.
2. Clinical presentation
A 30-year-old male with a past medical history of adult-onset
Still's disease diagnosed 1.5 years ago was transferred from an
outside hospital with fever, jaundice, weight loss, and impending
respiratory failure. On physical exam, there was splenomegaly and
imaging demonstrated retroperitoneal lymphadenopathy and pul-
monary inﬁltrates. Lab ﬁndings revealed pancytopenia and liver
function tests were suggestive of severe hepatitis. Signiﬁcant labora-
tory ﬁndings included total bilirubin 10.2 mg/dL (reference range
0.3–1.2 mg/dL), alkaline phosphatase 410 IU/L (30–115 IU/L), AST
320 IU/L (10–41 IU/L), ALT 476 IU/L (10–40 IU/L), LDH 749 IU/L (110–
240 IU/L), ferritin 14,298 ng/mL (23–336 ng/mL), WBC 2100/µL
(4300–10,300/µL), hemoglobin 7.5 g/dL (14.0–18.0 g/dL), and platelet
count 68,000/μL (140,000–440,000/μL). An extensive infectious dis-
ease workup did not reveal an etiology. Concern for hemophagocytic
lymphohistiocytosis was raised and a bone marrow biopsy was
performed.
3. Pathologic ﬁndings
Bone marrow aspirate smears were hemodilute but notable for
frequent macrophages exhibiting erythro- and leukophagocytosis
(Fig. 1A). Bone biopsy demonstrated absent normal hematopoiesis
and diffuse inﬁltration by lymphocytes and histiocytes (Fig. 1B). CD20
highlighted scattered, large atypical cells (Fig. 1C) that were negative
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/lrr
Leukemia Research Reports
http://dx.doi.org/10.1016/j.lrr.2014.05.004
2213-0489/& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
n Corresponding author. Tel.: þ1 508 793 6100; fax: þ1 508 793 6110.
E-mail address: benjamin.chen@umassmemorial.org (B.J. Chen).
Leukemia Research Reports 3 (2014) 42–45
for CD15 and CD30. The background inﬁltrate was composed
predominantly of T cells with a cytotoxic phenotype (CD3þ ,
CD5þ , CD7þ , CD8þ , and TIA-1þ [Fig. 2]), with admixed CD68þ-
histiocytes (Fig. 2D). Flow cytometry analysis did not show evidence
of an abnormal B- or T-cell population. Polymerase chain reaction
studies did not detect clonal IgH@, IgK@ or TCR gene rearrangements,
although neoplastic cells were scant. in situ hybridization for Epstein
Barr virus (EBV)-encoded RNA was negative.
A diagnosis of hemophagocytic lymphohistiocytosis arising in a
background of T-cell/histiocyte-rich large B-cell lymphoma was made.
Fig. 1. Aspirate smear showing examples of hemophagocytosis, Wright Geimsa stain, 1000 (A). Bone marrow core biopsy showing diffuse lymphohistiocytic inﬁltration
effacing the normal marrow architecture with scattered large atypical cells (arrows), H&E stain, 400 (B), inset 1000. CD20 immunostain highlights large neoplastic B
cells, 400 (C), inset 1000.
Fig. 2. Bone marrow core biopsy stained with antibody for CD3 (A) and CD8 (B) showing diffuse lymphocytic inﬁltrate. TIA-1 (C) demonstrates punctate staining of cytotoxic
T cells. CD68 (D) highlights admixed histiocytes. (A, B, D: 400, C: 600).
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This case was sent for expert review at an outside institution, and the
diagnosis was upheld. Biopsies of the retroperitoneal lymph node and
lung inﬁltrate also demonstrated involvement by THRLBCL.
4. Clinical management
Diagnostic criteria for HLH were updated in 2004 and rely on a
combination of clinical, laboratory, pathologic, and genetic results
(Table 1) [3,4]. Further laboratory workup for the patient revealed
hypertriglyceridemia (1040 mg/dL; reference range o150 mg/dL),
hypoﬁbrinogenemia (113 mg/dL; 150–400 mg/dL), and elevated
soluble IL-2 receptor (7469 U/mL; 45–1105 U/mL). NK cell function
was within normal limits. Thus, this patient fulﬁlled 7 out of
8 criteria for the diagnosis of HLH. Primary HLH was considered
unlikely given the patient's age, and studies on peripheral blood
did not show abnormalities in expression of perforin, granzyme B,
SLAM-associated protein, or X-linked inhibitor of apoptosis [3,4].
The patient did show a very low titer of EBV DNA (278 IU/mL) of
uncertain signiﬁcance, which was undetectable 3 weeks into
treatment.
Upon diagnosis, the patient's lymphoma and HLH represented
a therapeutic dilemma. Effective early therapy reduces mortality of
HLH from 95% to 30–35% [4]. The HLH-2004 treatment protocol
consists of T-cell targeted immunosupression with dexamethasone
and cyclosporine, macrophage targeted etoposide with intrathecal
methotrexate, if indicated, and monthly IV immunoglobulin [4]. In
addition, patients with THRLBCL should be treated similarly to
DLBCL with anthracycline-based chemotherapy and an anti-CD20
monoclonal antibody. Complicating this scenario was the patient's
multiorgan failure with severe hepatitis and high total bilirubin
levels, which represent contraindications to many chemotherapy
agents. As etoposide has signiﬁcantly impacted survival outcome
in HLH and induced sustained remissions of HLH, a full dose was
administered per HLH-2004 despite being contraindicated in liver
failure [4]. Three weeks later, when the patient's HLH had
responded (ferritin decreased from 14,298 to 3056 ng/mL), a
treatment with dose-adjusted EPOCH (etoposide, prednisone,
vincristine, cyclophosphamide, doxorubicin) with rituximab was
started. This regimen was selected as it contains etoposide, and
doses for subsequent cycles can be adjusted based on cytopenias,
avoiding the use of G-CSF which can be catastrophic in HLH [5].
The patient achieved remission as conﬁrmed by clinical and
laboratory workup, including follow-up bone marrow biopsy, and will
be further consolidated with an autologous stem cell transplant.
5. Discussion
Recent studies of genetic HLH have shed light on the patho-
physiology of the disease. Defects in cytotoxic pathways of T cells
and NK cells are thought to lead to an inability to clear antigenic
stimuli, resulting in a “cytokine storm” and perpetuation of the
inﬂammatory response [1]. Unchecked macrophage activation,
hemophagocytosis, and tissue inﬁltration ensue.
Acquired HLH is most often associated with infections (49%), of
which EBV is the most common, followed by malignancies (27%),
rheumatologic disorders (7%) and immune deﬁciency syndromes
(6%) [1]. Still's disease, also known as systemic-onset juvenile
idiopathic arthritis, is a form of juvenile rheumatoid arthritis that
carries an overall risk of HLH of 10% [6]. In our particular case, the
relationship between the patient's hematologic malignancy and
underlying autoimmune disorder, diagnosed as adult-onset Still's
disease, is unclear.
When HLH is associated with malignancy, T- and NK-cell
leukemias/lymphomas predominate, although HLH has also been
seen with anaplastic large cell lymphoma, other leukemias, and
solid tumors. HLH association with non-Hodgkin B-cell lymphoma
is relatively rare, involving predominantly older patients (460
years), with sparing of the bone marrow, as compared with T- or
NK-cell lymphomas [2].
T-cell/histiocyte-rich large B cell lymphoma accounts for 1–3% of
DLBCL, presents more commonly in males with a median age of 30
years, and typically pursues an aggressive clinical course. Diagnosis is
based on the identiﬁcation of o10% large neoplastic B cells in a
background of cytotoxic T cells and histiocytes [7]. Immunohisto-
chemistry can assist with differentiation from nodular lymphocyte-
predominant Hodgkin lymphoma and lymphocyte-rich classical
Hodgkin lymphoma by demonstrating expression of pan-B cell
markers and absence of CD15 and CD30 in large cells, along with a
cytotoxic phenotype of the background lymphocytes. Molecular
analysis for IGH@/IGK@ gene rearrangements can assist in demon-
strating clonality; however, the paucity of neoplastic cells in THRLBCL
can diminish the sensitivity of this PCR based assay leading to false-
negative results [8].
From a pathophysiologic standpoint, it is of interest that HLH
arose in the setting of THRLBCL in this patient. Although THRLBCL
is a B-cell malignancy, it is unique in that the predominant cell
population consists of cytotoxic T cells and histiocytes. Recent
gene expression proﬁling studies have suggested that the tumor
microenvironment of THRLBCL in fact favors a tolerogenic host
immune response despite the abundance of apparently ineffective
cytotoxic T cells [9]. In addition, both the tumor cells as well as the
inﬁltrating histiocytes have been shown to express the immune
suppressive molecule PD-L1, presumably as a mechanism for
tumor immune evasion, representing a potential target for therapy
[10]. Interestingly, in 1999, Mitterer, et al. [11], reported one other
case of HLH-associated THRLBCL, which was associated with
reactivated EBV infection, again raising the possibility that the
overall host immune environment contributes to disease manifes-
tation. Further studies examining the interplay between systemic
immune hyperactivation, tumor-mediated immune suppression,
and autoimmunity in cases of malignancy-associated HLH are
warranted to uncover novel and directed therapeutic approaches.
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Revised diagnostic guidelines for HLH [3].
Molecular diagnosis consistent with HLH
(PRF1, UNC13D, STXBP2, RAB27A, STX11, SH2D1A, or XIAP)
OR
Z5 of the following 8 diagnostic criteria:
Fever
Splenomegaly
Cytopenias (affectingZ2 of 3 lineages)
Hemoglobino9 g/dL
Plateletso100,000/μL
Neutrophilso1000/μL
Hypertriglyceridemia and/or hypoﬁbrinogenemia
Fasting triglyceridesZ265 mg/dL
Fibrinogenr150 mg/dL
Hemophagocytosis in bone marrow, spleen, or lymph nodes
FerritinZ500 ng/mL
Decreased or absent NK-cell activity
Soluble CD25Z2400 U/mL
K. Devitt et al. / Leukemia Research Reports 3 (2014) 42–4544
[3] Henter J, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic
guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer
2007;48:124–31.
[4] Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic
lymphohistiocytosis. Blood 2009;118:4041–52.
[5] Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH che-
motherapy for untreated large B-cell lymphomas: a pharmacodynamic
approach with high efﬁcacy. Blood 2002;99:2685–93.
[6] Kelly A, Ramanan AV. Recognition and management of macrophage activation
syndrome in juvenile arthritis. Curr Opin Rheum 2007;19:477–81.
[7] De Wolf-Peeters C, Delabie J, Campo E, et al. T cell/histiocyte-rich large B-cell
lymphoma. In: Swerdlow SH, et al., editors. WHO classiﬁcation of tumours of
haematopoietic and lymphoid tissues. 4th ed.. Lyon: IARC Press; 2008.
p. 238–9.
[8] van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardiza-
tion of PCR primers and protocols for detection of clonal immunoglobulin and
T-cell receptor gene recombinations in suspect lymphoproliferations: report of
the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003;17:
2257–317.
[9] Van Loo P, Tousseyn T, Vanhentenrijk V, et al. T-cell/histiocyte-rich large B-
cell lymphoma shows transcriptional features suggestive of a tolerogenic host
immune response. Haematologica 2010;95:440–8.
[10] Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a
subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin
Cancer Res 2013;19:3462–73.
[11] Mitterer M, Pescosta N, McQuain C, et al. Epstein–Barr virus related
hemophagocytic syndrome in a T-cell rich B-cell lymphoma. Ann Oncol
1999;10:231–4.
K. Devitt et al. / Leukemia Research Reports 3 (2014) 42–45 45
